Recently, results indicate that the activation of TRPA1 expressed in myofibroblast, in addition to its anti-inflammatory function in IBD [83], might have significant therapeutic relevance in preventing fibrosis [85]. This evidence concerns the gene TRPA1 and irritable bowel syndrome.